Home › Funds › VanEck ETF Trust › VanEck Biotech ETF
Fund family: VanEck ETF Trust · Filed by VanEck ETF Trust (CIK 1137360) · SEC series S000034406
Ticker: BBH (C000105864)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 299 with, 6 against, 0 abstentions (not counted as with management). Shareholder proposals: 4 FOR, 2 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as VanEck ETF Trust’s manager page (28,640 ballot items across 55 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | VanEck ETF Trust | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 92.8% | 277 | 89.2% | 21,516 |
| Backed environmental and social shareholder proposals at US companies | n/a | 1 | 16.2% | 309 |
Each ballot item this fund voted is set against the votes of the other VanEck ETF Trust funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted the same way as most VanEck ETF Trust funds on all 13 items where a comparison was possible.
The same votes as “with management” above, by the sector of the company voted on. 68.5% of this fund’s 305 such votes could be given a sector; the other 96 (31.5%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 199 | 6 | 3.0% |
| Technology | 10 | 0 | 0.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 188 | 0 |
| Audit-related | 27 | 0 |
| Corporate Governance | 25 | 3 |
| Say-on-Pay | 24 | 0 |
| Compensation | 21 | 1 |
| Capital Structure | 19 | 0 |
| Extraordinary Transactions | 2 | 0 |
| Other Social Issues | 1 | 1 |
| Shareholder Rights and Defenses | 1 | 1 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Amgen Inc. | May 19, 2026 | $80M | 15 | 1 |
| Gilead Sciences, Inc. | April 30, 2026 | $74M | 15 | 3 |
| Moderna, Inc. | November 12, 2025 | $53M | 2 | 0 |
| Vertex Pharmaceuticals Incorporated | May 13, 2026 | $41M | 15 | 1 |
| Regeneron Pharmaceuticals, Inc. | June 12, 2026 | $34M | 7 | 0 |
| argenx SE | May 6, 2026 | $26M | 12 | 0 |
| Natera, Inc. | June 11, 2026 | $21M | 8 | 0 |
| argenx SE | November 18, 2025 | $21M | 1 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 19, 2026 | Amgen Inc. | Stockholder proposal to require an independent board chairman. Shareholder proposal | For | Against |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | For | Against |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| May 13, 2026 | Vertex Pharmaceuticals Incorporated | Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposal | For | Against |
| April 23, 2026 | IQVIA Holdings Inc. | If properly presented, a stockholder proposal concerning separate Chairman and Chief Executive Officer roles. Shareholder proposal | For | Against |
308 ballot items at 28 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, VanEck Biotech ETF (BBH) voted at 28 shareholder meetings of 26 companies, on 308 ballot items in all. Where management made a recommendation, the fund followed it on 98.0% of the items and voted against it 6 times. Its most frequent area of disagreement was corporate governance (3 of its votes against management). It voted on 6 shareholder proposals. It voted FOR the board's own proposals more often than VanEck ETF Trust's funds as a whole (92.8% against 89.2%). It voted the same way as most VanEck ETF Trust funds on every item where a comparison was possible.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of VanEck ETF Trust’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.